Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

269
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
269
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Current and Emerging Therapeutic Strategies for the Treatment of Duchenne Muscular Dystrophy.

Genes·2026
Same author

Dysferlin's C2A domain supports normal Ca2+ signaling and membrane repair in dysferlin-null myofibers.

The Journal of general physiology·2026
Same author

Flexible Multimodal Neuroimaging Fusion for Alzheimer's Disease Progression Prediction.

Applications of medical artificial intelligence. AMAI (Workshop) (4th : 2024 : Taejon-si, Korea)·2026
Same author

Randomized, double-blind study of zervimesine in mild to moderate Alzheimer's disease.

Journal of Alzheimer's disease : JAD·2026
Same author

Feasibility and Acceptability of Collaborative Augmented Reality for Older Adults and Companions: Protocol for a Randomized Controlled Trial.

JMIR research protocols·2026
Same author

Tau in Alzheimer's disease: Shaping the future patient journey.

The journal of prevention of Alzheimer's disease·2026
Same journal

Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Associations of self-reported obstructive sleep apnea with cognition and dementia risk in cognitively unimpaired middle-aged adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Cardiovascular-kidney-metabolic syndrome stage modifies the efficacy of intensive blood pressure control on cognitive outcomes: A post hoc analysis of SPRINT MIND.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Evidence of APOE4-related brain vulnerabilities in verbal memory systems in midlife women.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Changes in DNA methylation-based aging predicts brain damage and dementia and reflects life-course cardiovascular risk.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Ver todos los artículos relacionados

Video Experimental Relacionado

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Desarrollo de Fármacos

Hannah R Bulgart1, Miguel A Lopez Perez2, Gianni N Giarrano2

  • 1University of Kentucky, Lexington, KY, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
Resumen
Este resumen es generado por máquina.

La proteína recombinante TRIM72/MG53 (rhMG53) mejora la reparación de la membrana plasmática en modelos de la enfermedad de Alzheimer (EA). El tratamiento con esta proteína reduce la neurotoxicidad y la muerte celular causadas por la beta amiloide (Aβ), ofreciendo una estrategia terapéutica potencial para la EA.

Palabras clave:
TRIM72MG53reparación de membranasAlzheimerneurotoxicidadbeta amiloideterapia

Más Videos Relacionados

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

Videos de Experimentos Relacionados

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

446

Área de la Ciencia:

  • Neurociencia
  • Biología Celular
  • Bioquímica

Sus antecedentes:

  • La beta amiloide (Aβ) daña las membranas plasmáticas neuronales en la enfermedad de Alzheimer (EA), alterando los mecanismos de reparación.
  • Los estudios muestran defectos en la reparación de la membrana plasmática en modelos de ratón de EA y con líquido cefalorraquídeo (LCR) de pacientes con EA.
  • Investigación del potencial terapéutico de mejorar la reparación de membranas para contrarrestar la neurotoxicidad inducida por Aβ.

Objetivo del estudio:

  • Determinar si la TRIM72/MG53 recombinante (rhMG53) puede mejorar la capacidad de reparación de la membrana plasmática.
  • Evaluar si rhMG53 puede reducir la neurotoxicidad y la muerte celular en modelos de EA.
  • Evaluar la eficacia de rhMG53 en neuronas primarias tratadas con Aβ o LCR de EA.

Principales métodos:

  • Ensayo de daño por láser en cortes de cerebro de ratón y neuronas primarias utilizando el colorante FM4-64 para evaluar la capacidad de reparación de membranas.
  • Tratamiento con rhMG53, Aβ recombinante y LCR de pacientes con EA.
  • Medición de la muerte celular (yoduro de propidio), el calcio intracelular (Fluo-4) y el estrés oxidativo (CellROX).

Principales resultados:

  • rhMG53 aumentó significativamente la capacidad de reparación de membranas en cortes de cerebro de ratón APP/PS1, restaurando la cinética basal.
  • rhMG53 mejoró la reparación de membranas en neuronas primarias tratadas con Aβ o LCR de EA.
  • El tratamiento con rhMG53 disminuyó significativamente la muerte celular y los marcadores de neurotoxicidad en neuronas tratadas con Aβ.

Conclusiones:

  • La mejora de la reparación de la membrana plasmática con rhMG53 puede contrarrestar la neurotoxicidad inducida por Aβ en la EA.
  • rhMG53 muestra promesa como agente terapéutico para la enfermedad de Alzheimer.
  • Estudios futuros investigarán los efectos de rhMG53 en la función cognitiva y la patología de la EA en modelos de ratón.